Shell Asset Management Co. decreased its position in shares of AngioDynamics, Inc. (NASDAQ:ANGO – Get Rating) by 12.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,578 shares of the medical instruments supplier’s stock after selling 3,787 shares during the period. Shell Asset Management Co. owned 0.07% of AngioDynamics worth $551,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in ANGO. Pinebridge Investments L.P. bought a new stake in AngioDynamics during the fourth quarter worth approximately $55,000. DekaBank Deutsche Girozentrale bought a new stake in AngioDynamics during the fourth quarter worth approximately $100,000. Teacher Retirement System of Texas bought a new stake in AngioDynamics during the fourth quarter worth approximately $204,000. Cornerstone Investment Partners LLC bought a new stake in AngioDynamics during the fourth quarter worth approximately $229,000. Finally, Lazard Asset Management LLC bought a new stake in AngioDynamics during the fourth quarter worth approximately $247,000. Institutional investors own 93.91% of the company’s stock.
AngioDynamics Price Performance
NASDAQ ANGO opened at $23.26 on Wednesday. The stock has a market capitalization of $906.44 million, a P/E ratio of -34.21 and a beta of 0.90. AngioDynamics, Inc. has a 1 year low of $17.56 and a 1 year high of $32.00. The business’s fifty day moving average is $20.22 and its two-hundred day moving average is $21.31. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.24 and a current ratio of 1.93.
Insiders Place Their Bets
In other AngioDynamics news, SVP Dave Helsel sold 5,000 shares of AngioDynamics stock in a transaction that occurred on Friday, July 29th. The shares were sold at an average price of $22.44, for a total transaction of $112,200.00. Following the transaction, the senior vice president now directly owns 23,822 shares in the company, valued at approximately $534,565.68. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 4.80% of the company’s stock.
Analysts Set New Price Targets
Several brokerages recently commented on ANGO. Raymond James dropped their target price on AngioDynamics from $32.00 to $27.00 and set a “strong-buy” rating on the stock in a report on Wednesday, July 13th. TheStreet cut AngioDynamics from a “c-” rating to a “d+” rating in a report on Friday, July 8th. Finally, Canaccord Genuity Group dropped their price target on AngioDynamics from $40.00 to $35.00 in a report on Wednesday, July 13th. Two equities research analysts have rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $33.00.
AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally.
- Get a free copy of the StockNews.com research report on AngioDynamics (ANGO)
- AMD Q2 Earnings Beat Expectations Significantly, Is AMD A Buy?
- 3 Health Care Stocks in Great Financial Health
- Amazon Names Itself A Top Stock Of Q3 Contender
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Market Fundamentals Drive Results For The Williams Companies
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.